Immuneering Corporation announced on August 26, 2025, the closing of its previously announced private placement. The transaction resulted in total upfront gross proceeds of approximately $25 million, before deducting fees and expenses.
The company sold an aggregate of 6,329,113 unregistered shares of its Class A common stock at a purchase price of $3.95 per share, with some investors receiving pre-funded warrants. Additionally, accompanying purchase warrants to acquire 2,848,096 shares of Class A common stock were issued, with an exercise price of $5.50 per share.
This capital infusion from top-tier institutional and accredited investors is expected to significantly bolster Immuneering's financial position, providing crucial resources to advance its clinical programs, particularly its lead candidate, atebimetinib.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.